首頁 > 市場調查報告書 > 製藥

呼吸器

市場調查報告書

商品編碼

1448599

全球肺炎治療市場研究報告 - 2024 年至 2032 年行業分析、規模、佔有率、成長、趨勢和預測

Global Pneumonia Therapeutics Market Research Report - Industry Analysis, Size, Share, Growth, Trends and Forecast 2024 to 2032

出版日期: 2024年02月01日 | 出版商:

Value Market Research | 英文 230 Pages | 商品交期: 最快1-2個工作天內

價格

簡介目錄圖表

全球肺炎治療市場的需求預計將從2023年的44.4億美元達到2032年近89.6億美元的市場規模，2024-2032年研究期間的CAGR為8.12%。

肺炎治療是指旨在解決肺炎的醫學治療和干涉措施，肺炎是一種通常由細菌、病毒或真菌感染引起的發炎性肺部疾病。治療方法可能包括抗生素、抗病毒藥物、支持性治療，嚴重情況下還需住院治療。目標是消除病原體、緩解症狀並促進呼吸恢復，確保患者獲得最佳治療效果。

市場動態

肺炎治療市場受到呼吸道感染高發生率、人口老化、肺炎相關併發症持續存在等因素的影響。對肺炎認知的提高和早期診斷，加上治療選擇的進步，促進了市場的成長。對有效和有針對性的治療方案（包括抗生素和疫苗）的需求在推動市場方面發揮著至關重要的作用。此外，COVID-19 大流行等傳染病爆發的影響凸顯了肺炎治療和呼吸系統健康的重要性。專注於新型治療方式和個人化醫療的持續研發工作也有助於擴大肺炎治療市場。

該報告涵蓋波特五力模型、市場吸引力分析和價值鏈分析。這些工具有助於清晰地了解行業結構並評估全球範圍內的競爭吸引力。此外，這些工具也對全球肺炎治療市場的各個細分市場進行了包容性評估。肺炎治療產業的成長和趨勢為本研究提供了整體方法。

市場區隔

肺炎治療市場報告的這一部分透過在國家和地區層面進行分析，提供了有關細分市場的詳細資料，從而幫助策略師確定相應產品或服務的目標人群以及即將到來的機會。

按類型

細菌性肺炎
病毒性肺炎
黴菌性肺炎

按年齡段

孩子們
成人
老年科

依給藥途徑

口服
注射用
其他

按藥物類別

抗生素
抗病毒藥物
抗真菌藥物
皮質類固醇
其他（NSAIDs、止咳藥等）

按配銷通路

醫院藥房
零售藥局
網路藥局

區域分析

本節涵蓋區域前景，重點介紹北美、歐洲、亞太地區、拉丁美洲以及中東和非洲肺炎治療市場當前和未來的需求。此外，該報告重點關注所有主要地區各個應用領域的需求、估計和預測。

該研究報告還涵蓋了市場主要參與者的全面概況以及對全球競爭格局的深入了解。肺炎治療市場的主要參與者包括阿斯特捷利康、諾華公司、艾伯維公司、梯瓦製藥工業有限公司、輝瑞公司、賽諾菲、Lupin Pharmaceuticals, Inc.、Innoviva, Inc.、Wockhardt Ltd.、住友製藥有限公司、該部分包含競爭格局的整體視圖，包括各種策略發展，例如關鍵併購、未來產能、合作夥伴關係、財務概況、合作、新產品開發、新產品發布和其他發展。

如果您有任何客製化要求，請寫信給我們。我們的研究團隊可以根據您的需求提供客製化報告。

簡介 - 市場動態
市場促進因素
市場限制
機會
產業動態
波特五力分析
市場吸引力分析
- 按類型分類的市場吸引力分析
- 按年齡層別分類的市場吸引力分析
- 按給藥途徑進行的市場吸引力分析
- 按藥品類別分類的市場吸引力分析
- 按配銷通路分類的市場吸引力分析
- 市場吸引力分析：按地區

第 4 章：價值鏈分析

價值鏈分析
原料分析
- 原料清單
- 原料廠商清單
- 主要原物料價格走勢
潛在買家名單
行銷管道
- 直效行銷
- 間接行銷
- 行銷通路發展趨勢

第 5 章：全球肺炎治療市場分析：按類型

按類型概述
歷史和預測數據
按類型分析
細菌性肺炎
病毒性肺炎
黴菌性肺炎

第 6 章：全球肺炎治療市場分析：依年齡層別分類

依年齡層別概覽
歷史和預測數據
按年齡層分析
孩子們
成人
老年科

第 7 章：全球肺炎治療市場分析：按給藥途徑

依給藥途徑概述
歷史和預測數據
依給藥途徑分析
口服
注射用
其他

第 8 章：全球肺炎治療市場分析：依藥物類別

按藥物類別概述
歷史和預測數據
按藥物類別分析
抗生素
抗病毒藥物
抗真菌藥物
皮質類固醇
其他（非類固醇抗發炎藥、止咳藥等）

第 9 章：全球肺炎治療市場分析：按分銷管道

按配銷通路分類的概覽
歷史和預測數據
按配銷通路分析
醫院藥房
零售藥局
網路藥局

第 10 章：全球肺炎治療市場分析：依地理位置

區域展望
介紹
北美銷售分析
- 概覽、歷史與預測資料銷售分析
- 北美按細分市場銷售分析
- 北美按國家銷售分析
- 美國銷售分析
- 加拿大銷售分析
- 墨西哥銷售分析
歐洲銷售分析
- 概覽、歷史與預測資料銷售分析
- 歐洲按細分市場銷售分析
- 歐洲按國家銷售分析
- 英國銷售分析
- 法國銷售分析
- 德國銷售分析
- 義大利銷售分析
- 俄羅斯銷售分析
- 歐洲其他地區銷售分析
亞太地區銷售分析
- 概覽、歷史與預測資料銷售分析
- 亞太地區按細分市場銷售分析
- 亞太地區國家/地區銷售分析
- 中國銷售分析
- 印度銷售分析
- 日本銷售分析
- 韓國銷售分析
- 澳洲銷售分析
- 東南亞銷售分析
- 亞太地區其他地區銷售分析
拉丁美洲銷售分析
- 概覽、歷史與預測資料銷售分析
- 拉丁美洲按細分市場銷售分析
- 拉丁美洲按國家銷售分析
- 巴西銷售分析
- 阿根廷銷售分析
- 秘魯銷售分析
- 智利銷售分析
- 拉丁美洲其他地區銷售分析
中東和非洲銷售分析
- 概覽、歷史與預測資料銷售分析
- 中東和非洲按細分市場銷售分析
- 中東和非洲國家銷售分析
- 沙烏地阿拉伯銷售分析
- 阿拉伯聯合大公國銷售分析
- 以色列銷售分析
- 南非銷售分析
- 中東其他地區和非洲銷售分析

第 11 章：肺炎治療公司的競爭格局

肺炎治療市場競爭
夥伴關係/協作/協議
併購
新產品發布
其他發展

第 12 章：公司簡介

公司股份分析
市場集中度
AstraZeneca

公司簡介
公司收入
產品
最近的發展

Novartis AG

公司簡介
公司收入
產品
最近的發展

AbbVie Inc.

公司簡介
公司收入
產品
最近的發展

Teva Pharmaceutical Industries Ltd.

公司簡介
公司收入
產品
最近的發展

Pfizer Inc.

公司簡介
公司收入
產品
最近的發展

Sanofi

公司簡介
公司收入
產品
最近的發展

Lupin Pharmaceuticals Inc.

公司簡介
公司收入
產品
最近的發展

Innoviva Inc.

公司簡介
公司收入
產品
最近的發展

Wockhardt Ltd.

公司簡介
公司收入
產品
最近的發展

Sumitomo Pharma Co. Ltd.

公司簡介
公司收入
產品
最近的發展

注意 - 在公司概況中，財務詳細資訊和近期發展視情況而定，或者如果是私人公司，則可能不包括在內

簡介目錄圖表

Product Code: VMR112113744

The global demand for Pneumonia Therapeutics Market is presumed to reach the market size of nearly USD 8.96 Billion by 2032 from USD 4.44 Billion in 2023 with a CAGR of 8.12% under the study period 2024 - 2032.

Pneumonia therapeutics refers to the medical treatments and interventions aimed at addressing pneumonia, an inflammatory lung condition typically caused by bacterial, viral, or fungal infections. Therapeutic approaches may include antibiotics, antiviral medications, supportive care, and, in severe cases, hospitalization. The goal is to eliminate the causative agent, alleviate symptoms, and promote respiratory recovery, ensuring optimal patient outcomes.

MARKET DYNAMICS

The Pneumonia therapeutics market is influenced by factors such as the high prevalence of respiratory infections, increasing aging populations, and the persistence of pneumonia-related complications. Rising awareness and early diagnosis of pneumonia, coupled with advancements in therapeutic options, contribute to the market's growth. The demand for effective and targeted treatment options, including antibiotics and vaccines, plays a crucial role in driving the market. Additionally, the impact of infectious disease outbreaks, such as the COVID-19 pandemic, highlights the importance of pneumonia therapeutics and respiratory health. Ongoing research and development efforts focusing on novel treatment modalities and personalized medicine also contribute to the expansion of the pneumonia therapeutics market.

The report covers Porter's Five Forces Model, Market Attractiveness Analysis, and Value Chain analysis. These tools help to get a clear picture of the industry's structure and evaluate the competition attractiveness at a global level. Additionally, these tools also give an inclusive assessment of each segment in the global market of pneumonia therapeutics. The growth and trends of Pneumonia Therapeutics Industry provide a holistic approach to this study.

MARKET SEGMENTATION

This section of the pneumonia therapeutics market report provides detailed data on the segments by analyzing them at country and regional level, thereby assisting the strategist in identifying the target demographics for the respective product or services with the upcoming opportunities.

By Type

Bacterial Pneumonia
Viral Pneumonia
Fungal Pneumonia

By Age Group

Children
Adult
Geriatric

By Route Of Administration

Oral
Parenteral
Others

By Drug Class

Antibiotics
Antiviral Drugs
Antifungal Drugs
Corticosteroids
Others (NSAIDs, Cough Suppressant, Etc.)

By Distribution Channel

Hospital Pharmacies
Retail Pharmacies
Online Pharmacies

REGIONAL ANALYSIS

This section covers the regional outlook, which accentuates current and future demand for the Pneumonia Therapeutics market across North America, Europe, Asia-Pacific, Latin America, and Middle East & Africa. Further, the report focuses on demand, estimation, and forecast for individual application segments across all the prominent regions.

The research report also covers the comprehensive profiles of the key players in the market and an in-depth view of the competitive landscape worldwide. The major players in the pneumonia therapeutics market include AstraZeneca, Novartis AG, AbbVie Inc., Teva Pharmaceutical Industries Ltd., Pfizer Inc., Sanofi, Lupin Pharmaceuticals, Inc., Innoviva, Inc., Wockhardt Ltd., Sumitomo Pharma Co., Ltd. This section consists of a holistic view of the competitive landscape that includes various strategic developments such as key mergers & acquisitions, future capacities, partnerships, financial overviews, collaborations, new product developments, new product launches, and other developments.

In case you have any custom requirements, do write to us. Our research team can offer a customized report as per your need.

1 . PREFACE

1.1. Report Description
- 1.1.1. Objective
- 1.1.2. Target Audience
- 1.1.3. Unique Selling Proposition (USP) & offerings
1.2. Research Scope
1.3. Research Methodology
- 1.3.1. Market Research Process
- 1.3.2. Market Research Methodology

2 . EXECUTIVE SUMMARY

2.1. Highlights of Market
2.2. Global Market Snapshot

3 . PNEUMONIA THERAPEUTICS - INDUSTRY ANALYSIS

3.1. Introduction - Market Dynamics
3.2. Market Drivers
3.3. Market Restraints
3.4. Opportunities
3.5. Industry Trends
3.6. Porter's Five Force Analysis
3.7. Market Attractiveness Analysis
- 3.7.1 Market Attractiveness Analysis By Type
- 3.7.2 Market Attractiveness Analysis By Age Group
- 3.7.3 Market Attractiveness Analysis By Route of Administration
- 3.7.4 Market Attractiveness Analysis By Drug Class
- 3.7.5 Market Attractiveness Analysis By Distribution Channel
- 3.7.6 Market Attractiveness Analysis By Region

4 . VALUE CHAIN ANALYSIS

4.1. Value Chain Analysis
4.2. Raw Material Analysis
- 4.2.1. List of Raw Materials
- 4.2.2. Raw Material Manufactures List
- 4.2.3. Price Trend of Key Raw Materials
4.3. List of Potential Buyers
4.4. Marketing Channel
- 4.4.1. Direct Marketing
- 4.4.2. Indirect Marketing
- 4.4.3. Marketing Channel Development Trend

5 . GLOBAL PNEUMONIA THERAPEUTICS MARKET ANALYSIS BY TYPE

5.1 Overview by Type
5.2 Historical and Forecast Data
5.3 Analysis by Type
5.4 Bacterial Pneumonia Historic and Forecast Sales by Regions
5.5 Viral Pneumonia Historic and Forecast Sales by Regions
5.6 Fungal Pneumonia Historic and Forecast Sales by Regions

6 . GLOBAL PNEUMONIA THERAPEUTICS MARKET ANALYSIS BY AGE GROUP

6.1 Overview by Age Group
6.2 Historical and Forecast Data
6.3 Analysis by Age Group
6.4 Children Historic and Forecast Sales by Regions
6.5 Adult Historic and Forecast Sales by Regions
6.6 Geriatric Historic and Forecast Sales by Regions

7 . GLOBAL PNEUMONIA THERAPEUTICS MARKET ANALYSIS BY ROUTE OF ADMINISTRATION

7.1 Overview by Route of Administration
7.2 Historical and Forecast Data
7.3 Analysis by Route of Administration
7.4 Oral Historic and Forecast Sales by Regions
7.5 Parenteral Historic and Forecast Sales by Regions
7.6 Others Historic and Forecast Sales by Regions

8 . GLOBAL PNEUMONIA THERAPEUTICS MARKET ANALYSIS BY DRUG CLASS

8.1 Overview by Drug Class
8.2 Historical and Forecast Data
8.3 Analysis by Drug Class
8.4 Antibiotics Historic and Forecast Sales by Regions
8.5 Antiviral Drugs Historic and Forecast Sales by Regions
8.6 Antifungal Drugs Historic and Forecast Sales by Regions
8.7 Corticosteroids Historic and Forecast Sales by Regions
8.8 Others (NSAIDs, Cough suppressant, etc.) Historic and Forecast Sales by Regions

9 . GLOBAL PNEUMONIA THERAPEUTICS MARKET ANALYSIS BY DISTRIBUTION CHANNEL

9.1 Overview by Distribution Channel
9.2 Historical and Forecast Data
9.3 Analysis by Distribution Channel
9.4 Hospital Pharmacies Historic and Forecast Sales by Regions
9.5 Retail Pharmacies Historic and Forecast Sales by Regions
9.6 Online Pharmacies Historic and Forecast Sales by Regions

10 . GLOBAL PNEUMONIA THERAPEUTICS MARKET ANALYSIS BY GEOGRAPHY

10.1. Regional Outlook
10.2. Introduction
10.3. North America Sales Analysis
- 10.3.1. Overview, Historic and Forecast Data Sales Analysis
- 10.3.2. North America By Segment Sales Analysis
- 10.3.3. North America By Country Sales Analysis
- 10.3.4. United State Sales Analysis
- 10.3.5. Canada Sales Analysis
- 10.3.6. Mexico Sales Analysis
10.4. Europe Sales Analysis
- 10.4.1. Overview, Historic and Forecast Data Sales Analysis
- 10.4.2. Europe by Segment Sales Analysis
- 10.4.3. Europe by Country Sales Analysis
- 10.4.4. United Kingdom Sales Analysis
- 10.4.5. France Sales Analysis
- 10.4.6. Germany Sales Analysis
- 10.4.7. Italy Sales Analysis
- 10.4.8. Russia Sales Analysis
- 10.4.9. Rest Of Europe Sales Analysis
10.5. Asia Pacific Sales Analysis
- 10.5.1. Overview, Historic and Forecast Data Sales Analysis
- 10.5.2. Asia Pacific by Segment Sales Analysis
- 10.5.3. Asia Pacific by Country Sales Analysis
- 10.5.4. China Sales Analysis
- 10.5.5. India Sales Analysis
- 10.5.6. Japan Sales Analysis
- 10.5.7. South Korea Sales Analysis
- 10.5.8. Australia Sales Analysis
- 10.5.9. South East Asia Sales Analysis
- 10.5.10. Rest Of Asia Pacific Sales Analysis
10.6. Latin America Sales Analysis
- 10.6.1. Overview, Historic and Forecast Data Sales Analysis
- 10.6.2. Latin America by Segment Sales Analysis
- 10.6.3. Latin America by Country Sales Analysis
- 10.6.4. Brazil Sales Analysis
- 10.6.5. Argentina Sales Analysis
- 10.6.6. Peru Sales Analysis
- 10.6.7. Chile Sales Analysis
- 10.6.8. Rest of Latin America Sales Analysis
10.7. Middle East & Africa Sales Analysis
- 10.7.1. Overview, Historic and Forecast Data Sales Analysis
- 10.7.2. Middle East & Africa by Segment Sales Analysis
- 10.7.3. Middle East & Africa by Country Sales Analysis
- 10.7.4. Saudi Arabia Sales Analysis
- 10.7.5. UAE Sales Analysis
- 10.7.6. Israel Sales Analysis
- 10.7.7. South Africa Sales Analysis
- 10.7.8. Rest Of Middle East And Africa Sales Analysis

11 . COMPETITIVE LANDSCAPE OF THE PNEUMONIA THERAPEUTICS COMPANIES

11.1. Pneumonia Therapeutics Market Competition
11.2. Partnership/Collaboration/Agreement
11.3. Merger And Acquisitions
11.4. New Product Launch
11.5. Other Developments

12 . COMPANY PROFILES OF PNEUMONIA THERAPEUTICS INDUSTRY

12.1. Company Share Analysis
12.2. Market Concentration Rate
12.3. AstraZeneca
- 12.3.1. Company Overview
- 12.3.2. Company Revenue
- 12.3.3. Products
- 12.3.4. Recent Developments
12.4. Novartis AG
- 12.4.1. Company Overview
- 12.4.2. Company Revenue
- 12.4.3. Products
- 12.4.4. Recent Developments
12.5. AbbVie Inc.
- 12.5.1. Company Overview
- 12.5.2. Company Revenue
- 12.5.3. Products
- 12.5.4. Recent Developments
12.6. Teva Pharmaceutical Industries Ltd.
- 12.6.1. Company Overview
- 12.6.2. Company Revenue
- 12.6.3. Products
- 12.6.4. Recent Developments
12.7. Pfizer Inc.
- 12.7.1. Company Overview
- 12.7.2. Company Revenue
- 12.7.3. Products
- 12.7.4. Recent Developments
12.8. Sanofi
- 12.8.1. Company Overview
- 12.8.2. Company Revenue
- 12.8.3. Products
- 12.8.4. Recent Developments
12.9. Lupin Pharmaceuticals Inc.
- 12.9.1. Company Overview
- 12.9.2. Company Revenue
- 12.9.3. Products
- 12.9.4. Recent Developments
12.10. Innoviva Inc.
- 12.10.1. Company Overview
- 12.10.2. Company Revenue
- 12.10.3. Products
- 12.10.4. Recent Developments
12.11. Wockhardt Ltd.
- 12.11.1. Company Overview
- 12.11.2. Company Revenue
- 12.11.3. Products
- 12.11.4. Recent Developments
12.12. Sumitomo Pharma Co. Ltd.
- 12.12.1. Company Overview
- 12.12.2. Company Revenue
- 12.12.3. Products
- 12.12.4. Recent Developments